Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

This publication has 12 references indexed in Scilit:

• Management Guidelines for Mucopolysaccharidosis VI
  Pediatrics, 2007
• Six-Minute Walk Test in Children and Adolescents
  The Journal of Pediatrics, 2007
• Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
  The Journal of Pediatrics, 2006
• Physiologic response of the six-minute walk test in children with juvenile idiopathic arthritis
  Arthritis & Rheumatism, 2005
• Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase
  Pediatrics, 2005
• Six-Minute Walking Test to Assess Exercise Tolerance and Cardiorespiratory Responses During Training Program in Children With Congenital Heart Disease
  International Journal of Sports Medicine, 2005
• Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
  American Journal of Medical Genetics Part A, 2005
• Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
  The Journal of Pediatrics, 2004
• A Qualitative Systematic Overview of the Measurement Properties of Functional Walk Tests Used in the Cardiorespiratory Domain
  Chest, 2001
• The six-minute walking test in children with cystic fibrosis: Reliability and validity
  Pediatric Pulmonology, 1996